Xeris Biopharma Holdings Inc XERS
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-21 |
| Shares Out. | 172,640,000 |
| Website | xerispharma.com/ ↗ |
| Phone | 18444455704 |
| Employees | 435 |
| Revenue | $83.1M |
| Gross Profit | $72.6M |
| Net Income | $2.2M |
| Free Cash Flow | $47.5M |
| Total Assets | $392.0M |
| Total Liabilities | $379.0M |
| Equity | $13.0M |
About Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Xeris Biopharma Holdings Inc is a publicly traded company under the ticker symbol XERS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)